@inproceedings{inproceedings, title  = {{SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)}},

 url = {{}},

 year = {{2019}},

 month = {{10}},

 author = {{Nathan P and Needham A and Corrie PG and Danson S and Evans J and Ochsenreither S and Kumar S and Goodman A and Larkin JMG and Karydis I and Steven NM et al}},

 volume = {{30}},

 journal = {{ANNALS OF ONCOLOGY}},

 note = {{Accessed on 2024/09/19}}}